-
Mashup Score: 0What are the initial results of ADC-based combinations? - 2 year(s) ago
The Multiple Myeloma Hub was pleased to speak to Rajshekhar Chakraborty, Herbert Irving Comprehensive Cancer Center, New York, US. We asked, What are the initial results of antibodyâdrug conjugate (ADC)-based combinations?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The PROMISE study: What have we learnt about MGUS prevalence and clinical implications? - 2 year(s) ago
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you seen this? #COMy22 | đ„ The MM Hub was pleased to speak to @IreneGhobrial, @DanaFarber. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications? #myeloma #mmsm https://t.co/5SgDHBJ5RW
-
-
Mashup Score: 1
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-UniversitĂ€t WĂŒrzburg, WĂŒrzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„Weekend Rewatch During the #COMy22, the Multiple Myeloma Hub was pleased to speak to @H_Einsele, Hermann Einsele, Julius-Maximilians-UniversitĂ€t WĂŒrzburg. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma? https://t.co/9CklcTJHkw #MMsm
-
-
Mashup Score: 0What are the current and future strategies for maintenance therapy after autologous transplant? - 2 year(s) ago
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to MarĂa-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the current and future strategies for maintenance therapy after autologous transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ Weekend watch! During #COMy22, the MM Hub was pleased to speak to MarĂa-Victoria Mateos, University Hospital of Salamanca. We asked, What are the current and future strategies for maintenance therapy after autologous transplant? https://t.co/0eIrqHXtW9
-
-
Mashup Score: 1Classification and treatment of frail and ultra frail patients with multiple myeloma: challenges and future perspectives - 2 year(s) ago
Here, we review an oral presentation, given on May 15, 2022, at the 8th World Congress on Controversies in Multiple Myeloma (COMy) by Sonja Zweegman, on the management of ultra-frail patients with MM, identifying potential conflict between the aims of MM treatment (e.g., length of survival) and the patientsâ own priorities (e.g., quality of life).
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #COMy22, Sonja Zweegman discussed how ultra-frail patients with multiple #myeloma are at higher risk of treatment discontinuation and adverse outcomes and how crucial it is to identify them in the clinic accurately. Read a summary heređ #mmsm #gerionc https://t.co/DBYkB32CpN https://t.co/FR03Agjy1a
-
-
Mashup Score: 0What are the initial results of ADC-based combinations? - 2 year(s) ago
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Rajshekhar Chakraborty, Herbert Irving Comprehensive Cancer Center, New York, US. We asked, What are the initial results of antibodyâdrug conjugate (ADC)-based combinations?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ During the #COMy22 , the MM Hub was pleased to speak to @rajshekharucms, Herbert Irving Comprehensive Cancer Center. We asked, What are the initial results of antibodyâdrug conjugate (ADC)-based combinationsâ Watch the video here đ https://t.co/d6yKPUdAGY
-
-
Mashup Score: 1The PROMISE study: What have we learnt about MGUS prevalence and clinical implications? - 2 year(s) ago
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ During the #COMy22, the MM Hub was pleased to speak to @IreneGhobrial, @DanaFarber. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implicationsâ #myeloma #mmsm https://t.co/5SgDHBJ5RW
-
-
Mashup Score: 3
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-UniversitĂ€t WĂŒrzburg, WĂŒrzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ During the #COMy22, the Multiple Myeloma Hub was pleased to speak to @H_Einsele, Julius-Maximilians-UniversitĂ€t WĂŒrzburg. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myelomaâ https://t.co/9CklcTJ9uY
-
-
Mashup Score: 1
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Ajai Chari, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Which targets are being explored in myeloma with bispecific antibodies?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ During #COMy22, the MM Hub was pleased to speak to @AjaiChari, @IcahnMountSinai. We asked, Which targets are being explored in myeloma with bispecific antibodiesâ https://t.co/1kYYUfEVDy
-
-
Mashup Score: 2What are the current and future strategies for maintenance therapy after autologous transplant? - 2 year(s) ago
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to MarĂa-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the current and future strategies for maintenance therapy after autologous transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ„ During #COMy22, the MM Hub was pleased to speak to MarĂa-Victoria Mateos, University Hospital of Salamanca. We asked, What are the current and future strategies for maintenance therapy after autologous transplantâ https://t.co/0eIrqHXtW9
-
Have you seen this? #COMy22 | đ„ The MM Hub was pleased to speak to @rajshekharucms, Herbert Irving Comprehensive Cancer Center. We asked, What are the initial results of antibodyâdrug conjugate (ADC)-based combinations? Watch the video here đ https://t.co/d6yKPUe8ww